Image de couverture de livre

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Chien‐Wei Su
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
par: Elisa Pinto, et autres
Publié: (2026)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
par: Yixuan Zhu, et autres
Publié: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
par: Pei‐Chien Tsai, et autres
Publié: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
par: Pei‐Chien Tsai, et autres
Publié: (2026)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
par: Yinghan Chen, et autres
Publié: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
par: Daniel Q. Huang, et autres
Publié: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
par: Takefumi Kimura
Publié: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
par: Chunlong Liu, et autres
Publié: (2025)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
par: Wei‐Fan Hsu, et autres
Publié: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
par: Shun‐Ichi Wakabayashi, et autres
Publié: (2026)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
par: Ibrahima Gueye
Publié: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
par: Yuanyan Sun, et autres
Publié: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
par: Zhejin Shi, et autres
Publié: (2026)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
par: Gamal Shiha, et autres
Publié: (2025)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
par: Rosellina M. Mancina, et autres
Publié: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
par: R. Sinha, et autres
Publié: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Global Burden of Gallbladder Cancer Attributable to Modifiable Risk Factors
par: Daniele Piovani, et autres
Publié: (2025)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
par: Stine Johansen, et autres
Publié: (2026)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
par: Jee‐Fu Huang, et autres
Publié: (2026)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
par: Marco Vincenzo Lenti, et autres
Publié: (2025)

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma
par: Ashwini Arvind, et autres
Publié: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
par: Suprabhat Giri, et autres
Publié: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
par: Jessica D. Lee, et autres
Publié: (2025)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
par: Leon A. Adams, et autres
Publié: (2026)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
par: Ziheng Calvin Xu, et autres
Publié: (2025)

MELD 3.0 Improves Risk Stratification and Mortality Prediction in Hepatorenal Syndrome‐Acute Kidney Injury: A Multicentre Study
par: Jing Ma, et autres
Publié: (2025)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
par: Kelly Torosian, et autres
Publié: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
par: Einar S. Björnsson
Publié: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
par: Karen Cheuk‐Ying Ho, et autres
Publié: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
par: Einar S. Björnsson
Publié: (2025)

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
par: Kunhee Kim, et autres
Publié: (2024)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
par: Jia‐Yong Su, et autres
Publié: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
par: Na Tian, et autres
Publié: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Shinya Yokoyama, et autres
Publié: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
par: C. C. Mark Cheah, et autres
Publié: (2025)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
par: Nobuharu Tamaki, et autres
Publié: (2025)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
par: Wah Loong Chan, et autres
Publié: (2024)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
par: Raj Vuppalanchi, et autres
Publié: (2025)